Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study

Abstract GABRIELL was a phase II single-arm study to evaluate the efficacy and safety of obinutuzumab plus bendamustine for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Seventy-two patients with active disease received treatment for up to six 28-day cycles. Overall response rate was 78.6% with a median progression-free survival (PFS) of 26 months, and overall survival (OS) not reached at the end of follow-up (36 months). Undetectable measurable residual disease (≤0.01%; 36.4% in bone marrow and 53.4% in peripheral blood) correlated with a significantly longer PFS and OS (vs. >0.01). Common grade ≥3 adverse events (76.4%) were neutropenia (58.3%), thrombocytopenia (26.4%) and febrile neutropenia (11.1%). TP53 disruption was the only independent predictive factor for response (Hazard ratio; HR: 0.228). Unmutated immunoglobulin heavy chain variable region (HR: 16.061) was a negative prognostic factor for PFS. In conclusion, the combination of obinutuzumab plus bendamustine is an active and generally adequately-tolerated treatment for R/R CLL.

[1]  T. Robak.  Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia? , 2023, Leukemia & lymphoma.

[2]  V. Prasad,et al.  Front‐line chronic lymphocytic leukemia: The role of chemoimmunotherapy , 2023, American journal of hematology.

[3]  M. Hallek,et al.  Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients , 2022, Leukemia & lymphoma.

[4]  T. Shanafelt,et al.  Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial , 2022, Blood.

[5]  C. Dearden,et al.  Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia , 2022, Blood advances.

[6]  J. Pagel,et al.  Current and future treatment strategies in chronic lymphocytic leukemia , 2021, Journal of Hematology & Oncology.

[7]  M. Hernández-Sánchez,et al.  From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct , 2021, Cancers.

[8]  G. Gaidano,et al.  A step ahead toward precision medicine for chronic lymphocytic leukemia , 2020, Haematologica.

[9]  R. Foà,et al.  Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia , 2019, Haematologica.

[10]  E. González-Barca,et al.  High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance , 2019, Haematologica.

[11]  T. Kipps,et al.  Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Thompson,et al.  Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. , 2018, Cancer discovery.

[13]  Scott E. Smith,et al.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL , 2018, The New England journal of medicine.

[14]  M. Hallek,et al.  Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma , 2018, Leukemia.

[15]  F. Bosch,et al.  Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study , 2018, Haematologica.

[16]  F. Bosch,et al.  Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study , 2018, Leukemia.

[17]  D. Rossi,et al.  The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. , 2017, Hematology. American Society of Hematology. Education Program.

[18]  A. López-Guillermo,et al.  Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia , 2017, Leukemia.

[19]  P. Evans,et al.  Minimal residual disease is an independent predictor for 10-year survival in CLL. , 2016, Blood.

[20]  W. Klapper,et al.  First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. , 2016, The Lancet. Oncology.

[21]  F. Stingo,et al.  Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. , 2016, Blood.

[22]  W. Wierda,et al.  Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. , 2016, Blood.

[23]  H. Döhner,et al.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. , 2016, Blood.

[24]  A. López-Guillermo,et al.  Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.

[25]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[26]  J. Byrd,et al.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.

[27]  E. Giné,et al.  The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy , 2014, Haematologica.

[28]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[29]  Michalis K. Titsias,et al.  SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. , 2014, Blood.

[30]  M. Cazzola,et al.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.

[31]  H. Döhner,et al.  Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[33]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[34]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[35]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[36]  An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. , 2016, The Lancet. Oncology.